Coave Therapeutics SA has nominated a lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration and diabetic macular edema.
Innovstone Therapeutics Ltd. has disclosed integrin αLβ2 (LFA-1)/ICAM-1 interaction inhibitors and/or RASP-trapping agents reported to be useful for the treatment of dry eye syndrome.
Researchers at Carl von Ossietzky Universität Oldenburg generated retinal pigment epithelial cell lines lacking three RPGR isoforms and examined whether they showed the defects in ciliary structure and actin turnover known to occur in retinitis pigmentosa.
University of Eastern Finland has synthesized carbonic anhydrase II (CA2) inhibitors and melanin ligands. As such, they are described as potentially useful for the treatment of glaucoma, macular edema and retinal degeneration.
Shenzhen Newrosetta Biosciences Co. Ltd. has described deuterated derivatives of AF-DX 116 acting as muscarinic M2 receptor antagonists reported to be useful for the treatment of myopia.
Aniridia-associated keratopathy (AAK) is a rare genetic eye condition caused by PAX6 haploinsufficiency, which leads to chronic inflammation, neovascularization and vision loss. Currently, there are limited therapeutic options for the treatment of AAK, which has been linked to limbal stem cell deficiency.
Hypoxia-inducible factors (HIFs) play a central role in how retinal cells respond to low oxygen, but their chronic activation has been linked to the development of age-related macular degeneration (AMD) and related retinal disorders.
Primary open-angle glaucoma (POAG) is among the leading causes of irreversible blindness. Early detection and treatment are crucial for vision preservation, and research to identify genes associated with POAG is ongoing.
RSS
